糖尿病是一種以高血糖為特征的代謝性疾病，目前常用的口服降糖藥均需要每天服藥，給患者帶來不便。奧格列汀是一個小分子二肽基肽酶-4（DPP-4）抑制劑，由默克公司研發(fā)，主要用于二型糖尿病的治療，且只需1周服用1次即可，從而提高了患者的順應(yīng)性和堅(jiān)持性，最終提高了治療效果。介紹了奧格列汀的合成方法、藥理學(xué)、藥物代謝動力學(xué)、臨床研究等信息，為更好地應(yīng)用臨床與研發(fā)類似新藥提供依據(jù)。

Diabetes is a kind of metabolic disease characterized by hyperglycemia The oral hypoglycemic agents used currently are required to take every day, which brings inconvenience to patients. Omarigliptin is a small molecule DPP-4 (depeptidyl peptidase-4) inhibitor. The drug is developed by the Merck Co, mainly for the treatment of type two diabetes. The drug only need to be taken once a week, so as to improve the patient's compliance and adherence, thereby improving the therapeutic effect. This article introduces the information of omarigliptin from the aspects of synthesis, pharmacology, pharmacokinetics, and clinical research, which provides valuable information for pharmaceutical workers.